360 related articles for article (PubMed ID: 32103870)
41. Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer.
Mutze K; Langer R; Becker K; Ott K; Novotny A; Luber B; Hapfelmeier A; Göttlicher M; Höfler H; Keller G
Ann Surg Oncol; 2010 Dec; 17(12):3336-43. PubMed ID: 20585871
[TBL] [Abstract][Full Text] [Related]
42. Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin.
Robert C; Nagaria PK; Pawar N; Adewuyi A; Gojo I; Meyers DJ; Cole PA; Rassool FV
Leuk Res; 2016 Jun; 45():14-23. PubMed ID: 27064363
[TBL] [Abstract][Full Text] [Related]
43. Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.
Tung B; Ma D; Wang S; Oyinlade O; Laterra J; Ying M; Lv SQ; Wei S; Xia S
BMC Cancer; 2018 Oct; 18(1):1025. PubMed ID: 30348136
[TBL] [Abstract][Full Text] [Related]
44. The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways.
Hrgovic I; Doll M; Kleemann J; Wang XF; Zoeller N; Pinter A; Kippenberger S; Kaufmann R; Meissner M
BMC Cancer; 2016 Sep; 16(1):763. PubMed ID: 27716272
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
[TBL] [Abstract][Full Text] [Related]
46. HDACi: cellular effects, opportunities for restorative dentistry.
Duncan HF; Smith AJ; Fleming GJ; Cooper PR
J Dent Res; 2011 Dec; 90(12):1377-88. PubMed ID: 21536971
[TBL] [Abstract][Full Text] [Related]
47. Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma.
Collier CD; Getty PJ; Greenfield EM
Adv Exp Med Biol; 2020; 1258():55-75. PubMed ID: 32767234
[TBL] [Abstract][Full Text] [Related]
48. Combination Therapies Targeting HDAC and IKK in Solid Tumors.
Vancurova I; Uddin MM; Zou Y; Vancura A
Trends Pharmacol Sci; 2018 Mar; 39(3):295-306. PubMed ID: 29233541
[TBL] [Abstract][Full Text] [Related]
49. Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma.
Phimmachanh M; Han JZR; O'Donnell YEI; Latham SL; Croucher DR
Front Cell Dev Biol; 2020; 8():578770. PubMed ID: 33117806
[TBL] [Abstract][Full Text] [Related]
50. Repurposing of triamterene as a histone deacetylase inhibitor to overcome cisplatin resistance in lung cancer treatment.
To KKW; Cheung KM; Cho WCS
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7217-7234. PubMed ID: 36905422
[TBL] [Abstract][Full Text] [Related]
51. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
Marchion DC; Bicaku E; Daud AI; Richon V; Sullivan DM; Munster PN
J Cell Biochem; 2004 May; 92(2):223-37. PubMed ID: 15108350
[TBL] [Abstract][Full Text] [Related]
52. Targeting Histone Deacetylases in Diseases: Where Are We?
Benedetti R; Conte M; Altucci L
Antioxid Redox Signal; 2015 Jul; 23(1):99-126. PubMed ID: 24382114
[TBL] [Abstract][Full Text] [Related]
53. HDAC inhibitors activate lipid peroxidation and ferroptosis in gastric cancer.
Jenke R; Oliinyk D; Zenz T; Körfer J; Schäker-Hübner L; Hansen FK; Lordick F; Meier-Rosar F; Aigner A; Büch T
Biochem Pharmacol; 2024 Jul; 225():116257. PubMed ID: 38705532
[TBL] [Abstract][Full Text] [Related]
54. Histone deacetylase inhibitor quisinostat activates caspase signaling and upregulates p53 acetylation to inhibit the proliferation of HepG2 cells.
Li F; Wang T; Wang Z; Chen X; Liu R
Mol Med Rep; 2017 Nov; 16(5):6094-6101. PubMed ID: 28849080
[TBL] [Abstract][Full Text] [Related]
55. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates.
Marchion DC; Bicaku E; Daud AI; Sullivan DM; Munster PN
Mol Cancer Ther; 2005 Dec; 4(12):1993-2000. PubMed ID: 16373714
[TBL] [Abstract][Full Text] [Related]
56. p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death.
Mrakovcic M; Kleinheinz J; Fröhlich LF
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31096697
[TBL] [Abstract][Full Text] [Related]
57. Ginsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells.
Liu ZH; Li J; Xia J; Jiang R; Zuo GW; Li XP; Chen Y; Xiong W; Chen DL
Chem Biol Interact; 2015 Dec; 242():227-34. PubMed ID: 26482938
[TBL] [Abstract][Full Text] [Related]
58. Histone Deacetylases (HDAC) Inhibitor-Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor.
Drzewiecka M; Gajos-Michniewicz A; Hoser G; Jaśniak D; Barszczewska-Pietraszek G; Sitarek P; Czarny P; Piekarski J; Radek M; Czyż M; Skorski T; Śliwiński T
Genes (Basel); 2023 Jun; 14(6):. PubMed ID: 37372475
[TBL] [Abstract][Full Text] [Related]
59. Histone hyperacetylation during meiosis interferes with large-scale chromatin remodeling, axial chromatid condensation and sister chromatid separation in the mammalian oocyte.
Yang F; Baumann C; Viveiros MM; De La Fuente R
Int J Dev Biol; 2012; 56(10-12):889-99. PubMed ID: 23417411
[TBL] [Abstract][Full Text] [Related]
60. Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.
Ali SR; Humphreys KJ; McKinnon RA; Michael MZ
Drug Dev Res; 2015 Sep; 76(6):296-317. PubMed ID: 26303212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
